Listed by the USPTO as HUYNH, PHUONG N
Tech Center 1600 • Art Units: 1641 1643 1644
This examiner grants 66% of resolved cases
HUYNH, PHUONG N is an examiner in tech center 1600 and art unit 1641. The profile records 1350 resolved cases, a 65.8% allowance rate, and a median of 1140 days to allowance. Its 53.6% interview lift is a substantial positive signal within this record, indicating that interview participation is closely associated with improved allowance outcomes.
The principal companies are Hoffmann-La Roche Inc., Janssen Pharmaceuticals Inc., and The University of Toledo. The listed firms are Knobbe, Martens, Olson & Bear, LLP, Ipsilon USA - NLO, and Lathrop GPM LLP | Sanofi-Aventis. Applicants may benefit from planning interviews early enough to address examination concerns before prosecution becomes prolonged, while preserving clear technical and legal support for any amendments.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18282503 | CHIMERIC PHAGOCYTIC RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 17507029 | THERAPEUTIC MULTISPECIFIC POLYPEPTIDES ACTIVATED BY POLYPEPTIDE CHAIN EXCHANGE | Non-Final OA | Hoffmann-La Roche Inc. |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | Non-Final OA | Hoffmann-La Roche Inc. |
| 17335702 | AFFINITY CHROMATOGRAPHY PURIFICATION WITH LOW CONDUCTIVITY WASH BUFFER | Non-Final OA | Hoffmann-La Roche Inc. |
| 17628418 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | Final Rejection | The Regents of the University of Michigan |
| 18178886 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | Non-Final OA | Novartis AG |
| 13885646 | AGENTS AND METHODS FOR TREATING DISEASES THAT CORRELATE WITH BCMA EXPRESSION | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 17771227 | COMBINED INHIBITION OF PD-1, TGFB AND TIGIT FOR THE TREATMENT OF CANCER | Non-Final OA | MERCK PATENT GmbH |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18702244 | HUMAN FC VARIANTS HAVING IMPROVED FCrRIIA BINDING SELECTIVITY | Non-Final OA | Korea University Research and Business Foundation |
| 18248345 | RATIONAL SELECTION OF BUILDING BLOCKS FOR THE ASSEMBLY OF MULTISPECIFIC ANTIBODIES | Non-Final OA | AMGEN INC. |
| 18256916 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | Non-Final OA | Purdue Research Foundation |
| 17961761 | NANOPARTICLE IMMUNOCONJUGATES | Final Rejection | The Curators of the University of Missouri |
| 18298743 | METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Final Rejection | SANOFI |
| 17782980 | ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | Non-Final OA | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18024486 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | Final Rejection | Dyne Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy65.8% of resolved applications examined by Phuong N Huynh were allowed (1,350 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +53.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Phuong N Huynh took 1,140 days on average from filing to allowance.
Phuong N Huynh examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
